Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy

Functionalized nanoparticles (NPs) represent a cutting edge in innovative clinical approaches, allowing for the delivery of selected compounds with higher specificity in a wider time frame. They also hold promise for novel theranostic applications that integrate both diagnostic and therapeutic funct...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2024-09, Vol.16 (9), p.1218
Main Authors: Mariotti, Melinda, Giacon, Noah, Lo Cascio, Ettore, Cacaci, Margherita, Picchietti, Simona, Di Vito, Maura, Sanguinetti, Maurizio, Arcovito, Alessandro, Bugli, Francesca
Format: Article
Language:English
Subjects:
Acids
Antibodies
Bone marrow
Cancer
Care and treatment
Cloning
Diabetes therapy
Drug delivery systems
E coli
Ethylenediaminetetraacetic acid
Fab
Glycoproteins
Health aspects
Herpes viruses
Hypoglycemic agents
Instrument industry
Ligands
Monoclonal antibodies
nano-immuno-probe
Nanoparticles
Nanotechnology
Peptides
PLGA
Polyethylene glycol
Proteins
Scientific equipment and supplies industry
Tetracycline
Tetracyclines
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Functionalized nanoparticles (NPs) represent a cutting edge in innovative clinical approaches, allowing for the delivery of selected compounds with higher specificity in a wider time frame. They also hold promise for novel theranostic applications that integrate both diagnostic and therapeutic functions. Pathogens are continuously evolving to try to escape the strategies designed to treat them. In this work, we describe the development of a biotechnological device, Nano-Immuno-Probes (NIPs), for early detection and infections treatment. Human Herpes Simplex Virus 2 was chosen as model pathogen. NIPs consist of PLGA-PEG-Sulfone polymeric NPs conjugated to recombinant Fab antibody fragments targeting the viral glycoprotein G2. NIPs synthesis involved multiple steps and was validated through several techniques. DLS analysis indicated an expected size increase with a good polydispersity index. Z-average and z-potential values were measured for PLGA-PEG-Bis-Sulfone NPs (86.6 ± 10.9 nm; -0.7 ± 0.3 mV) and NIPs (151 ± 10.4 nm; -5.1 ± 1.9 mV). SPR assays confirmed NIPs' specificity for the glycoprotein G2, with an apparent of 1.03 ± 0.61 µM. NIPs exhibited no cytotoxic effects on VERO cells at 24 and 48 h. This in vitro study showed that NIPs effectively target HSV-2, suggesting the potential use of these nanodevices to deliver both contrast agents as well as therapeutic compounds.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics16091218